GAITHERSBURG, Md., March 6, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in TD Cowen's 43rd Annual Health Care Conference.
Conference Details: | ||||||
Fireside Chat | ||||||
Date: | Wednesday, March 8, 2023 | |||||
Time: | 9:50 – 10:20 a.m. Eastern Standard Time (EST) | |||||
Location: | Boston Marriott Copley Place in Boston, Massachusetts | |||||
Moderator: | Georgi Yordanov, Equity Research Analyst – Biotechnology | |||||
Novavax participant: | John Trizzino, Chief Commercial Officer and Chief Business Officer | |||||
Conference | ||||||
Event: | Investor Meetings | |||||
Date: | Wednesday, March 8, 2023 | |||||
Recordings
A replay of the recorded fireside session will be available through the Events & presentations page of the Company's website at ir.novavax.com for 90 days from the date of the conference.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information.
CONTACTS
Investors
Erika Schultz
240-268-2022
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media
Ali Chartan
240-720-7804
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$6.20 |
| Daily Change: | -0.19 -2.97 |
| Daily Volume: | 3,711,183 |
| Market Cap: | US$993.120M |
April 15, 2025 March 11, 2025 February 27, 2025 December 13, 2024 December 10, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
